Capricor Therapeutics CAPR EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Capricor Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Capricor Therapeutics’s 10-Q, filed November 10, 2025, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's EBITDA margin?
- Capricor Therapeutics (CAPR) reported EBITDA margin of -762.9% in Q3 2025.
- How has Capricor Therapeutics's EBITDA margin changed year-over-year?
- Capricor Therapeutics's EBITDA margin decreased by 409.4% year-over-year, from -149.8% to -762.9%.
- What is the long-term trend for Capricor Therapeutics's EBITDA margin?
- Over 2 years (2020 to 2024), Capricor Therapeutics's EBITDA margin has grown at a -79.4% compound annual growth rate (CAGR), from -4,366.2% to -184.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.